Good afternoon :)
$
₹
T

TriSalus Life Sciences Inc.

TLSIW

NASDAQ
T

TriSalus Life Sciences Inc.

TLSIW

NASDAQ
$0.936.89% (+0.06)
$
₹
$0.936.89% (+0.06)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Unknown

Sector and industry information not available

Unknown

Recent listing (market-cap unavailable as on date)

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

—
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-62.59%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Peers

Peers

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Financials

Financials

Income

Balance Sheet

Cash Flow

11.5
-10.8
13.2
-9.7
8.8
1.5
11.4
-9.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue6.457.367.348.269.1611.2111.5613.208.8911.40
Net Income-13.20-4.33-2.39-10.10-10.37-8.28-10.81-9.751.53-9.18
Net Profit Margin-204.52%-58.82%-32.64%-122.35%-113.17%-73.91%-93.47%-73.85%17.29%-80.53%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. TriSalus Life Sciences Inc. (TLSIW) share price today is $0.93 as of September 5, 2026 at 1:29 AM IST. The stock touched a day high of $0.93 and a day low of $0.93.

  2. TriSalus Life Sciences Inc. stock trades on NASDAQ under the ticker symbol TLSIW.

  3. TriSalus Life Sciences Inc.'s market capitalization is N/A as of September 5, 2026 at 1:29 AM IST.

  4. TriSalus Life Sciences Inc.'s price-to-earnings (P/E) ratio is N/A as of September 7, 2026.

  5. TriSalus Life Sciences Inc.'s price-to-book (P/B) ratio is 0 as of September 7, 2026.

  6. Yes, You can buy TriSalus Life Sciences Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy TriSalus Life Sciences Inc. shares in three steps: 1. Search TriSalus Life Sciences Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since TriSalus Life Sciences Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in TriSalus Life Sciences Inc. (TLSIW) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 10.7526 shares at the current price of $0.93.

Loading...